What this article helps you consider
- Identify the relevant solid state question
- Combine complementary techniques
- Examine the material in its product context
Identify the relevant solid state question
Polymorphs have the same chemical composition but different crystal structures. Hydrates and solvates contain water or solvent within the solid structure and require related but distinct consideration. Amorphous material lacks the long-range order of a crystal. Pharmaceutical guidance sometimes addresses these forms together for practical control purposes, but the underlying distinctions remain useful.
FDA’s pharmaceutical solid-polymorphism guidance concerns ANDA chemistry and manufacturing information. It provides a regulatory context for assessing relevance to product performance; it should not be described as a requirement that every possible solid form must be routinely tested in every product. R49R11
Combine complementary techniques
X-ray powder diffraction can identify characteristic crystalline patterns and help detect changes in form. Differential scanning calorimetry examines thermal events such as melting, glass transition and crystallisation where detectable. Thermogravimetric analysis helps investigate mass changes associated with heating. Microscopy and spectroscopy can provide additional evidence.
A single thermal event does not always establish a unique form. Events can overlap, and the sample may transform during heating. Similarly, a weak diffraction pattern can reflect low concentration, small crystallites or matrix effects rather than complete amorphous character. The illustration illustrates idealised patterns only; it is not a reference spectrum for any substance.
Synthetic signals for no named substance. Not reference patterns; they cannot identify or quantify a real material.
Examine the material in its product context
An isolated ingredient can change during milling, wet processing, drying, compression or storage. Water and solvents can promote transformations, while excipients may influence crystallisation or analytical detection. Characterise the state that matters to the finished product rather than relying solely on an incoming-material result.
For a hypothetical tablet containing a low concentration of active ingredient, the excipient pattern may dominate the diffraction result. The method must demonstrate that it can answer the intended question at the actual product concentration. A negative finding below the method’s sensitivity is not proof that a minor form is absent.
Relate form to a measurable consequence
Potential differences include dissolution, apparent solubility, mechanical behaviour and stability. Establish whether a form change affects an attribute that needs control. A detectable transformation does not automatically imply a clinically meaningful problem, while a subtle change can be important if it alters release or process consistency.
An amorphous dispersion may show promising initial dissolution but recrystallise during storage. Assess physical stability alongside chemical stability and performance. Faster release in one laboratory medium does not by itself prove improved human absorption.
Design the investigation to avoid artefacts
Control preparation, grinding, humidity and thermal history. Sample treatment intended to improve measurement can itself change the form. Compare as-received and prepared material when needed, and document storage between sampling and analysis. Retain representative material for follow-up.
A useful study might combine controlled-humidity exposure with diffraction, water determination and dissolution. The experimental design should test a defined mechanism, such as hydration-related conversion, rather than collect unrelated measurements without a decision framework.
Establish controls proportional to relevance
Where a form is important, specify an appropriate material attribute, process control or finished-product test. Methods for identity and quantitative determination of a minor form have different performance needs. Reference materials should be suitably characterised and maintained under conditions that preserve their state.
Stabicon can support the integration of material characterisation with formulation and analytical work, including defining when specialised complementary testing is needed. The objective is to understand which physical-state changes matter and how they can be controlled.
References & further reading
Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.
- R49FDA ANDAs Pharmaceutical Solid Polymorphism
Final guidance, July 2007. ANDA chemistry, manufacturing and controls scope.
- R11ICH Q6A Specifications for Chemical Drug Substances and Products
FDA guidance page. Pharmaceutical specifications and dosage-form considerations.
- R05ICH Q14 Analytical Procedure Development
Final guideline adopted November 2023. Development and lifecycle approaches.
From insight to a defined programme
Bring your next technical question.
Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.
Discuss this topic with Stabicon






